1. In Vivo
  2. >>Business Strategy

Cardio-Neuro Innovator LivaNova Prepares For Challenges Ahead

 
• By Ashley Yeo
 
• 9 min read
 
Generate a summary of this article
Listen to this article
Beta

LivaNova was formed from the merger of cardiovascular disease therapy company Sorin Group and neuromodulation innovator Cyberonics. The role and place in the industry of this new mega group might not be obvious to all, but incoming CEO Damien McDonald already has a vision of creating a disciplined company that leverages synergies and gets closer to the customer base.

IV1703_Livanova_1200x675

"Quite sudden" and "a bit humbling." These are just some of the words that incoming LivaNova PLC CEO Damien McDonald uses to describe his rapid elevation to the position of head of the group – and on this particular occasion he was addressing investors at the Jefferies Global Healthcare Conference in London last November, ahead of his official installation as CEO on January 1, 2017.

McDonald had been drafted in from Danaher Corp. as chief operating officer of the NASDAQ-listed company in early October...

More from Business Strategy

More from In Vivo

It Pays To Be Different: Philips’ Take On Purpose-Driven Imaging & Ultrasound

 
• By Ashley Yeo

During his 40 years at Royal Philips, Bert van Meurs has seen the medical devices business grow in line with the evolving needs of healthcare providers with whom the company partners in customer and patient focused innovation.

Compugen’s Former Head Reflects on Computational Discovery, Strategic Collaborations And AI

 
• By David Wild

Anat Cohen-Dayag explains how Compugen transformed from computational service provider to clinical-stage biotech by integrating AI with biology and structuring strategic pharma collaborations.

Lupin Eyes Global Ophthalmology Growth

 
• By Lucie Ellis-Taitt

Entering 2026, Lupin is positioning itself for growth, with a keen focus on the expanding ophthalmology market.